Your browser doesn't support javascript.
loading
Biochemical screening for SARS-CoV-2 main protease inhibitors.
Coelho, Camila; Gallo, Gloria; Campos, Claudia B; Hardy, Leon; Würtele, Martin.
Afiliación
  • Coelho C; Department of Science and Technology, Federal University of São Paulo, São José dos Campos, Brazil.
  • Gallo G; Department of Science and Technology, Federal University of São Paulo, São José dos Campos, Brazil.
  • Campos CB; Department of Science and Technology, Federal University of São Paulo, São José dos Campos, Brazil.
  • Hardy L; Department of Physics, University of South Florida, Tampa, FL, United States of America.
  • Würtele M; Department of Science and Technology, Federal University of São Paulo, São José dos Campos, Brazil.
PLoS One ; 15(10): e0240079, 2020.
Article en En | MEDLINE | ID: mdl-33022015
ABSTRACT
The Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) pandemic represents a global challenge. SARS-CoV-2's ability to replicate in host cells relies on the action of its non-structural proteins, like its main protease (Mpro). This cysteine protease acts by processing the viruses' precursor polyproteins. As proteases, together with polymerases, are main targets of antiviral drug design, we here have performed biochemical high throughput screening (HTS) with recombinantly expressed SARS-CoV-2 Mpro. A fluorescent assay was used to identify inhibitors in a compound library containing known drugs, bioactive molecules and natural products. These screens led to the identification of 13 inhibitors with IC50 values ranging from 0.2 µM to 23 µM. The screens confirmed several known SARS-CoV Mpro inhibitors as inhibitors of SARS-CoV-2 Mpro, such as the organo-mercuric compounds thimerosal and phenylmercuric acetate. Benzophenone derivatives could also be identified among the most potent screening hits. Additionally, Evans blue, a sulfonic acid-containing dye, could be identified as an Mpro inhibitor. The obtained compounds could be of interest as lead compounds for the development of future SARS-CoV-2 drugs.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 3_ND Problema de salud: 3_neglected_diseases / 3_zoonosis Asunto principal: Antivirales / Neumonía Viral / Inhibidores de Proteasas / Proteínas no Estructurales Virales / Infecciones por Coronavirus / Evaluación Preclínica de Medicamentos / Betacoronavirus Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Brasil

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Contexto en salud: 3_ND Problema de salud: 3_neglected_diseases / 3_zoonosis Asunto principal: Antivirales / Neumonía Viral / Inhibidores de Proteasas / Proteínas no Estructurales Virales / Infecciones por Coronavirus / Evaluación Preclínica de Medicamentos / Betacoronavirus Tipo de estudio: Diagnostic_studies / Screening_studies Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2020 Tipo del documento: Article País de afiliación: Brasil
...